Physician profile
Michael J Mason
NPI 1487926549
$2,859.31
in general payments reported to CMS, 2019-2025
21 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $224 · 2023: $351 · 2024: $517 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,044.49 | 2021-2025 | |
| Madrigal Pharmaceuticals | $300.86 | 2025 | Rezdiffra |
| Genzyme Corporation | $157.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $148.55 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $141.33 | 2022-2023 | Rebyota |
| Gilead Sciences, INC. | $134.63 | 2021-2024 | Livdelzi |
| Novo Nordisk INC | $127.05 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $121.13 | 2021 | |
| Pfizer INC. | $101.45 | 2021-2025 | |
| Janssen Biotech, INC. | $99.19 | 2025 | Tremfya, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.71 | 2021-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $68.03 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $66.61 | 2025 | Vowst |
| Enterra Medical, INC. | $61.59 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.35 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $41.50 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $33.36 | 2021-2023 | Sutab |
| Ardelyx, INC. | $22.73 | 2022 | |
| Medtronic, INC. | $21.16 | 2023 | Interstim |
| Janssen Pharmaceuticals, INC | $17.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.